PCML
SPRY icon

Pavaki Capital Management LLC’s ARS Pharmaceuticals SPRY Stock Holding History

Pavaki Capital Management LLC’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,500
Closed -$17.5K – 161
2025
Q4 		$17.5K Buy
+1,500
New +$14.6K 0.01% 131

Other funds holding SPRY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
ELI
Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.36B AUM 25.57% 1-Year Est. Return
IMA
Investment Management Associates Greenwood Village, Colorado $487M AUM 11.51% 1-Year Est. Return

Pavaki Capital Management LLC's SPRY Position: Q2 2026 in Review

Pavaki Capital Management LLC increased its ARS Pharmaceuticals (SPRY) stake by 0.59% in Q2 2026, buying an estimated $29.2K and bringing the position to 579,600 shares worth $4.64M. The position accounts for 1.62% of the portfolio, ranked #14.

Pavaki Capital Management LLC first reported a position in SPRY in Q4 2025 and has held it in 3 quarters since. The position peaked at $13.7M in Q4 2025. 68 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Pavaki Capital Management LLC held 579,600 shares of ARS Pharmaceuticals worth $4.64M as of Q2 2026.
  • Pavaki Capital Management LLC bought 3,400 ARS Pharmaceuticals shares in Q2 2026, an estimated $29.2K.
  • ARS Pharmaceuticals made up 1.62% of Pavaki Capital Management LLC's portfolio in Q2 2026, its #14 holding.
  • Pavaki Capital Management LLC first reported a position in ARS Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Pavaki Capital Management LLC's ARS Pharmaceuticals position peaked at $13.7M in Q4 2025.
  • 68 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Pavaki Capital Management LLC's 13F filing for Q2 2026, filed 7 Aug 2026.